Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

LIVER CANCER

Therapy-induced senescence — an induced synthetic lethality in liver cancer?

Nature Reviews Gastroenterology & Hepatology volume 17, pages 135–136 (2020)Cite this article

Subjects

Cancer therapies, in addition to inducing cell death, can trigger cellular senescence of tumour cells, and factors secreted from senescent cells might negatively affect the tumour microenvironment. A new study by Wang et al. shows that eradication of therapy-induced senescent cells (senolysis) can improve the outcome of liver cancer therapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Exploiting therapy-induced senescence for improved cancer therapies.

References

  1. Frey, N. et al. Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics. Nat. Rev. Gastroenterol. Hepatol. 15, 81–95 (2018).

    Article  CAS  Google Scholar 

  2. Krtolica, A. et al. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA 98, 12072–12077 (2001).

    Article  CAS  Google Scholar 

  3. Eggert, T. et al. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression. Cancer Cell 30, 533–547 (2016).

    Article  CAS  Google Scholar 

  4. Wang, C. et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 574, 268–272 (2019).

    Article  CAS  Google Scholar 

  5. Toso, A. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 9, 75–89 (2014).

    Article  CAS  Google Scholar 

  6. Kang, T. W. et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547–551 (2011).

    Article  CAS  Google Scholar 

  7. Childs, B. G. et al. Senescent cells: an emerging target for diseases of ageing. Nat. Rev. Drug Discov. 16, 718–735 (2017).

    Article  CAS  Google Scholar 

  8. Chang, J. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78–83 (2016).

    Article  CAS  Google Scholar 

  9. Huang, A. et al. Synthetic lethality as an engine for cancer drug target discovery. Nat. Rev. Drug Discov. 19, 23–38 (2019).

    Article  Google Scholar 

  10. Bedard, P. L. et al. Tumour heterogeneity in the clinic. Nature 501, 355–364 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

L.Z. was supported by the Deutsche Forschungsgemeinschaft (FOR2314, SFB-TR209, Gottfried Wilhelm Leibniz Program) and the German Ministry for Education and Research (BMBF). Further funding was provided by the DFG under Germany’s excellence strategy EXC 2180-390900677 (Image Guided and Functionally Instructed Tumour Therapies (iFIT)), the Landesstiftung Baden-Wuerttemberg, the European Research Council (CholangioConcept) and the German Cancer Research Center (DKTK).

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tübingen, Tübingen, Germany

    Katharina Wolter & Lars Zender

  2. Cluster of Excellence ‘Image Guided and Functionally Instructed Tumor Therapies’ (iFIT), Eberhard-Karls University of Tübingen, Tübingen, Germany

    Katharina Wolter & Lars Zender

  3. German Consortium for Translational Cancer Research (DKTK), Partner Site Tübingen, German Cancer Research Center (DKFZ), Heidelberg, Germany

    Lars Zender

Authors
  1. Katharina Wolter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lars Zender
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lars Zender.

Ethics declarations

Competing interests

K.W. and L.Z. are listed as inventors on a patent relating to PET tracers for the non-invasive detection of cellular senescence.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wolter, K., Zender, L. Therapy-induced senescence — an induced synthetic lethality in liver cancer?. Nat Rev Gastroenterol Hepatol 17, 135–136 (2020). https://doi.org/10.1038/s41575-020-0262-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-020-0262-3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing